Fennec Pharmaceuticals/$FENC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Ticker
$FENC
Sector
Primary listing
Employees
35
Headquarters
Website
FENC Metrics
BasicAdvanced
$312m
-
-$0.28
0.91
-
Price and volume
Market cap
$312m
Beta
0.91
52-week high
$10.45
52-week low
$5.65
Average daily volume
340k
Financial strength
Current ratio
6.977
Quick ratio
6.149
Interest coverage (TTM)
-3.62%
Profitability
EBITDA (TTM)
-5.49
Gross margin (TTM)
92.23%
Net profit margin (TTM)
-16.42%
Operating margin (TTM)
-10.97%
Effective tax rate (TTM)
-1.28%
Revenue per employee (TTM)
$1,460,000
Management effectiveness
Return on assets (TTM)
-5.91%
Return on equity (TTM)
-52.68%
Valuation
Price to revenue (TTM)
5.329
Price to book
8.23
Price to tangible book (TTM)
8.23
Price to free cash flow (TTM)
-47.056
Free cash flow yield (TTM)
-2.13%
Free cash flow per share (TTM)
-0.191
Growth
Revenue change (TTM)
64.98%
Earnings per share change (TTM)
-47.43%
3-year revenue growth (CAGR)
151.34%
3-year earnings per share growth (CAGR)
-34.59%
10-year earnings per share growth (CAGR)
9.17%
FENC News
AllArticlesVideos
Adherex Technologies' PEDMARK Push Targets Larger AYA Market After Record Quarter
MarketBeat·4 weeks ago
Adherex Technologies Q1 Earnings Call Highlights
MarketBeat·1 month ago
Fennec Pharmaceuticals Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Newsfile Corp·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs